Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M646Revenue $M48.6Net Margin (%)-34.4Z-Score1.6
Enterprise Value $M493EPS $-2.2Operating Margin %-30.7F-Score6
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-33.9Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %0Quick Ratio12.1Cash flow > EarningsY
Price/Sales5.15-y EBITDA Growth Rate %-12.6Current Ratio12.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-23.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-37.4Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M28.4ROI % (ttm)-14.4Gross Margin Increase y-yY

Gurus Latest Trades with AEGR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AEGRGeorge Soros 2014-09-30 Buy 0.01%$26.93 - $35.65
($30.96)
$ 22.87-26%New holding, 25000 sh.25,000
AEGRJoel Greenblatt 2014-09-30 Buy $26.93 - $35.65
($30.96)
$ 22.87-26%New holding, 10964 sh.10,964
AEGRMichael Price 2014-06-30 Add0.16%$30.35 - $47.11
($37.32)
$ 22.87-39%Add 20%240,000
AEGRMichael Price 2014-03-31 Buy 1.1%$43.65 - $73.75
($59.26)
$ 22.87-61%New holding, 200000 sh.200,000
AEGRAndreas Halvorsen 2014-03-31 Sold Out -0.29%$43.65 - $73.75
($59.26)
$ 22.87-61%Sold Out0
AEGRAndreas Halvorsen 2013-09-30 Add0.33%$68.93 - $96.93
($85)
$ 22.87-73%Add 1969.2%744,788
AEGRAndreas Halvorsen 2013-06-30 Buy 0.01%$37.66 - $74.95
($53.09)
$ 22.87-57%New holding, 35994 sh.35,994
AEGRGeorge Soros 2012-06-30 Sold Out -0.01%$11.76 - $16.96
($14.02)
$ 22.8763%Sold Out0
AEGRGeorge Soros 2011-06-30 Buy 0.01%$15.29 - $21.85
($17.62)
$ 22.8730%New holding, 37500 sh.37,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AEGR is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AEGR George Soros 2014-09-3025,0000.090.01New Buy
AEGR Joel Greenblatt 2014-09-3010,9640.040New Buy
AEGR Michael Price 2014-09-30240,0000.841
Premium Most recent portfolio changes are included for Premium Members only!


AEGR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fitzpatrick Mark J.CFO 2014-08-19Buy1,150$30.64-25.55view
Beer Marc DCEO 2014-07-31Buy10,000$33.65-32.21view
Beer Marc DCEO 2014-06-03Buy10,000$30.12-24.27view
Beer Marc DCEO 2014-05-27Buy10,000$31.59-27.79view
Beer Marc DCEO 2014-05-20Buy10,000$30.53-25.29view
Beer Marc DCEO 2014-05-08Buy30,000$35.31-35.4view
VANLENT ANNEDirector 2014-05-08Buy4,000$33.78-32.47view
Fraser CraigPres., US/Int. Comm. & Manuf. 2014-04-30Sell2,250$43.55-47.62view
Fraser CraigPres., US/Int. Comm. & Manuf. 2014-03-31Sell2,250$46.2-50.63view
Sumeray MarkChief Medical Officer 2014-03-14Sell2,000$51.34-55.57view

Press Releases about AEGR :

    Quarterly/Annual Reports about AEGR:

      News about AEGR:

      Articles On GuruFocus.com
      Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
      Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
      Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
      Three CEOs Reporting Large Insider Buys May 22 2014 
      Four CEOs Reporting Large Insider Buys May 09 2014 
      100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
      My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
      Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

      More From Other Websites
      Nasdaq stocks posting largest volume increases Dec 18 2014
      Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Dec 08 2014
      Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Dec 08 2014
      SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible... Dec 01 2014
      Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference Nov 21 2014
      Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference Nov 21 2014
      AEGERION PHARMACEUTICALS, INC. Financials Nov 18 2014
      Hynes Keller & Hernandez, LLC Announces Investigations of M/A-Com Technology Solutions Holdings,... Nov 13 2014
      10-Q for Aegerion Pharmaceuticals, Inc. Nov 12 2014
      Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Nov 12 2014
      Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Nov 12 2014
      Aegerion to Acquire Myalept, Boost Portfolio - Shares Up Nov 11 2014
      AEGERION PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
      AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 07 2014
      Midday movers: Kate Spade, Apple, Hospira & more Nov 06 2014
      BUZZ- Aegerion Pharmaceuticals Inc: Buys AstraZeneca's rare disease drug Nov 06 2014
      Aegerion Buys Rare Disease Therapy, Seeking Path Out of Current Troubles Nov 06 2014
      AstraZeneca to divest Myalept to Aegerion Nov 06 2014
      Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca Nov 06 2014
      Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca Nov 06 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK